Core Viewpoint - The Central Economic Work Conference has signaled a strong focus on domestic demand and economic growth, leading to a significant rebound in Hong Kong's stock market, with the Hang Seng Index rising 1.75% to 25,976.79 points [1] Group 1: Market Performance - The Hang Seng Index saw a strong rebound, closing up 1.75% or 446.28 points, with a total trading volume of 242.657 billion HKD [1] - The Hang Seng Technology Index increased by 1.87%, while the Hang Seng China Enterprises Index rose by 1.62% [1] - Despite the daily gains, the Hang Seng Index recorded a weekly decline of 0.42% [1] Group 2: Blue-Chip Stocks - China Life (02628) led blue-chip gains, rising 5.52% to 28.3 HKD, contributing 17.61 points to the Hang Seng Index [2] - Other notable blue-chip performers included Cheung Kong Infrastructure (01038) up 4.55% and ZTO Express (02057) up 4.36% [2] - Some blue-chip stocks like Hengrui Medicine (03692) and Budweiser APAC (01876) experienced declines [2] Group 3: Sector Performance - Large technology stocks, including Tencent and Alibaba, rose over 2%, while Baidu increased by 1.78% [3] - Electric equipment stocks performed strongly, with Dongfang Electric rising over 13% [3] - The consumer sector was active, with companies like Tea Baidao (02555) and Haidilao (06862) showing significant gains [4] Group 4: Economic Policies - The Central Economic Work Conference emphasized the importance of domestic demand and outlined policies to boost consumption and urban renewal [5] - Investment strategies are shifting towards survival-type consumption, compensatory consumption, and defensive stocks [5] Group 5: Financial Sector - Brokerages and insurance stocks saw afternoon gains, with China Galaxy (06881) up 6.97% and China Life (02628) up 5.52% [6] - Regulatory changes are expected to allow insurance companies to increase their equity asset allocations [6] Group 6: Notable Stock Movements - Zhaoyan New Drug (06127) surged 19.75% amid supply shortages in the monkey breeding industry [7] - YTO Express (00038) rose 11.39% due to favorable conditions in agricultural modernization [8] - Conant Optical (02276) increased by 10% as production capacity for AI glasses is set to ramp up [9] - QZ Group (00917) rose 8.17% following a share buyback announcement [10] - ZTE Corporation (00763) gained 4% after announcing a share repurchase plan [11]

Core Viewpoint - The Hong Kong stock market is experiencing a positive trend, with the Hang Seng Index and Hang Seng Tech Index both showing gains, indicating a shift in investment logic towards new productivity and high-quality development [1] Market Performance - On December 12, the Hang Seng Index rose by 1.36% and the Hang Seng Tech Index increased by 1.45% [1] - Technology stocks saw widespread gains, while the metals sector led the increases [1] - The Hang Seng ETF (159920) rose nearly 2%, with notable performers including China Life, ZTO Express, China Hongqiao, and CK Infrastructure [1] - Conversely, companies like Hansoh Pharmaceutical, WuXi Biologics, and Zhongsheng Group experienced declines [1] Future Outlook - Jianyin International suggests that the investment logic for Hong Kong stocks has shifted from traditional valuation recovery to a revaluation based on new productivity and high-quality development [1] - There is potential for moderate expansion or improvement in valuations and earnings by 2026 [1] - Key catalysts and event windows include the reassessment of China's economic growth momentum at the start of the 14th Five-Year Plan, the Central Economic Work Conference in mid-December, and developments in US-China relations surrounding Trump's visit and the midterm elections [1] - Progress in AI capital expenditure and profitability is also highlighted as a significant factor [1] Notable Investment Targets - Core broad-based Hong Kong stock: Hang Seng ETF (159920) [1] - AI and platform economy focus: Hang Seng Tech Index ETF (513180) [1] - Focus on the development of Chinese enterprises in Hong Kong: Hang Seng China Enterprises ETF (159850) [1]

Market Overview - Hong Kong stocks opened positively with the Hang Seng Index up by 0.9%, the National Enterprises Index up by 0.88%, and the Hang Seng Technology Index up by 1.02% [1] - The market sentiment remains cautious, with expectations that the index will continue to fluctuate between 25,200 and 26,200 points [3] Company Updates - Zijin Mining (02899) saw a rise of 3.51%, while China Hongqiao (01378) increased by 3.32%, JD Health (06618) by 3.2%, Sands China (01928) by 2.36%, and NetEase (09999) by 1.91% [1] - Conversely, Henderson Land Development (00012) fell by 1.03%, Li Ning (02331) by 0.75%, and Hansoh Pharmaceutical (03692) by 0.65% [1] Bond Issuance - Zhaojin Mining (01818) opened high at 1.97% and announced the issuance of technology innovation convertible bonds amounting to 800 million RMB, which is 53.3% of the planned issuance of up to 1.5 billion RMB. The bonds have a two-year term and a coupon rate of 2.2% [1] Shareholder Activity - Leap Motor (09863) opened up by 1.63% as the Chairman and CEO Zhu Jiangming, along with shareholder Fu Liqian, purchased a total of 2.1506 million H shares at an average price of approximately 50.51 RMB, totaling over 100 million RMB. This increases their combined holdings to 23.75% of the total issued shares [2] - Red Star Macalline (01528) opened down by 0.84% after shareholders Taobao Holdings and New Retail Fund reduced their holdings by 30.616 million H shares, representing 0.7% of the current total share capital [2]

Core Insights - The top three companies by Hong Kong Stock Connect shareholding ratios are China Telecom (72.50%), Power Assets Holdings (69.68%), and GCL-Poly Energy Holdings (69.67%) [1][2] - Xiaomi Group-W, Tracker Fund of Hong Kong, and China Merchants Bank saw the largest increases in shareholding amounts over the last five trading days, with increases of +4.913 billion, +2.976 billion, and +1.548 billion respectively [1][2] - The companies with the largest decreases in shareholding amounts during the same period include WanGuo Gold Group (-3.816 billion), Tencent Holdings (-2.649 billion), and Alibaba Group-W (-1.421 billion) [1][2] Shareholding Ratios - The latest shareholding ratios for the top 20 companies in Hong Kong Stock Connect are led by: - China Telecom (100.63 billion shares, 72.50%) - Power Assets Holdings (3.72 billion shares, 69.68%) - GCL-Poly Energy Holdings (2.82 billion shares, 69.67%) [1] Recent Increases in Shareholding - The top 10 companies with the largest increases in shareholding amounts over the last five trading days are: - Xiaomi Group-W: +4.913 billion (11.647 million shares) - Tracker Fund of Hong Kong: +2.976 billion (11.551 million shares) - China Merchants Bank: +1.548 billion (3.028 million shares) [1][2] Recent Decreases in Shareholding - The top 10 companies with the largest decreases in shareholding amounts over the last five trading days are: - WanGuo Gold Group: -3.816 billion (-49.945 million shares) - Tencent Holdings: -2.649 billion (-4.403 million shares) - Alibaba Group-W: -1.421 billion (-9.435 million shares) [1][2]

Group 1 - ZTE Corporation's stock price dropped by 13.08% to HKD 27.50 per share due to a "black swan" event related to compliance investigations by the U.S. Department of Justice [3] - The company is in communication with the U.S. DOJ regarding compliance with the Foreign Corrupt Practices Act and is committed to maintaining its rights through legal means [3] - ZTE emphasizes its commitment to strengthening its compliance system and has a zero-tolerance policy towards corruption [3] Group 2 - Huayuan Securities has given ZTE a "buy" rating, projecting revenues of RMB 138.48 billion, RMB 156.64 billion, and RMB 174.41 billion for 2025 to 2027, with corresponding net profits of RMB 83.80 billion, RMB 89.37 billion, and RMB 103.79 billion [3] - The projected price-to-earnings ratios for ZTE are 17.57, 16.45, and 14.17 for the years 2025 to 2027 [3] - ZTE's core growth is expected to come from its computing business benefiting from the AI wave, with differentiated product advantages in its terminal business [4] Group 3 - The Hong Kong Stock Exchange appointed Graeme Farrell as the Group Chief Risk Officer, effective January 12, 2026, succeeding Richard Wise [5] - Farrell will oversee the risk management department, including credit and quantitative analysis, technology risk management, and enterprise risk management [6] - The CEO of the Hong Kong Stock Exchange highlighted Farrell's extensive international experience in risk management as a significant asset for enhancing market vitality and liquidity [6]

Group 1: Federal Reserve and Market Reaction - The Federal Reserve lowered interest rates by 25 basis points but maintained its forecast of only one rate cut in 2026 according to the dot plot [1] - Hong Kong stocks opened high but closed lower, with the Hang Seng Index down 0.04% to 25,530.51 points and a total turnover of HKD 182.48 billion [1] - The market is sensitive to external risks, with potential rebounds expected around mid-December and early January [1] Group 2: Blue-Chip Stocks Performance - HSBC Holdings reached a new high, closing up 2.06% at HKD 114, contributing 43.23 points to the Hang Seng Index [2] - Other blue-chip stocks like Hansoh Pharmaceutical and Henderson Land also saw gains, while Alibaba Health and Sands China faced declines [2] Group 3: Sector Performance - Large tech stocks generally declined, with Alibaba down 1.7% and Tencent down 0.25% [3] - The wind power sector remained strong, with Goldwind Technology and Dongfang Electric seeing significant gains [3] - Lithium battery stocks were active, with companies like CATL and Ganfeng Lithium showing positive performance amid rising production costs [4] Group 4: Chip Sector Developments - The U.S. government allowed NVIDIA to export its H200 AI chips to China, which may boost domestic AI development and increase demand for local chips [5] Group 5: Real Estate Sector Trends - Domestic property stocks generally fell, with notable declines in companies like Agile Group and Sunac China [6] - Discussions around mortgage interest subsidy policies have increased, which could stimulate potential homebuyer demand if implemented [6] Group 6: Notable Stock Movements - ZTE Corporation faced a significant drop of 13.08% following compliance investigation news [7] - Red Star Macalline's stock fell 14.39% due to unusual trading activity, despite the company stating that its operations remain normal [8] - Lens Technology experienced fluctuations, closing up 2.05% after announcing a potential acquisition [9] - Asia Financial Holdings surged 80.87% after announcing a voluntary cash offer for shares at a premium [10]

Group 1 - The core viewpoint is that the US economy is expected to maintain moderate growth next year, supported by factors such as Federal Reserve interest rate cuts and AI investments, while remaining strategically bullish on US stocks but cautious of structural differentiation and short-term risks in Q1 [1] - For the Hong Kong stock market outlook, it is anticipated that the market will shift from valuation-driven to profit growth-driven, with valuation expansion likely to weaken but liquidity remaining supportive [1] - The combination of profit-driven growth and liquidity support is expected to emerge by 2026, with new supply creating new demand as a new driving force for the Hong Kong stock market [1] Group 2 - The technology sector in the US stock market is expected to become more rational, with AI remaining a key driver, and the regulatory environment being favorable for mergers and acquisitions [1] - The AI advancements are projected to continue driving revenue and valuation recovery in the Chinese internet sector's cloud business [1] - The domestic pharmaceutical and innovative drug sectors are likely to benefit from a resurgence in mergers and acquisitions by large multinational pharmaceutical companies, as well as an increase in BD transactions [1] Group 3 - The automotive industry is expected to see flat or slightly declining sales next year, with current market sentiment being sufficiently pessimistic, presenting an opportunity to gradually accumulate stocks of companies with high earnings growth certainty [2] - The consumption sector's recovery remains uneven, suggesting a strategy of "anchoring on earnings while leveraging growth" for investment [2] - The education sector is viewed positively for its resilient growth and expansion opportunities [2] Group 4 - Recommended stocks for Q1 next year include: Alphabet (GOOGL.US), Meta (META.US), Netflix (NFLX.US), Tencent Holdings (00700), Alibaba (BABA.US), Bilibili (BILI.US), Hansoh Pharmaceutical (03692), CanSino Biologics-B (02162), Innovent Biologics (01801), and others [2]

Group 1 - The core viewpoint of the report highlights that the pharmaceutical industry in China is experiencing a reversal in 2025, driven by innovative drugs, with significant benefits observed in the CXO and upstream supply chain sectors, particularly in the Hong Kong stock market where innovative drugs have seen a rise of over 80% year-to-date [1][4] - The report emphasizes that the core catalyst for innovative drugs comes from policy support and the realization of business development (BD) opportunities abroad, with notable transactions exceeding 1 billion USD, validating the international competitiveness of Chinese innovative drugs [1][2] - A significant reform in the payment sector is underway, with the introduction of a dual-track system for medical insurance, allowing for the inclusion of high-value innovative drugs in commercial insurance, addressing the gap in coverage for expensive treatments [1][2] Group 2 - The report indicates a rapid growth trend in the number of license-out transactions by Chinese pharmaceutical companies, with total upfront payments reaching 6.298 billion USD, a 53% year-on-year increase, and total transaction amounts reaching 118.862 billion USD, a 125% increase [2] - Looking ahead to 2026, the report suggests a shift from "BD-driven" to "data-driven" investment in innovative drugs, emphasizing the importance of clinical data validation and commercial capabilities for revenue growth [2] - Recommended stocks for investment include Heng Rui Medicine, Kelun-Biotech, and Teva Biopharmaceuticals, among others, while companies like Kangfang Biotech and Innovent Biologics are suggested for further attention [2][3] Group 3 - The overall profitability of the pharmaceutical sector remains stable, with a gradual improvement in the profitability of the pharmaceutical manufacturing industry, despite a slight decline in revenue growth [11][15] - The report notes a significant divergence within the industry, with the medical services sector performing well, while the profits of the biopharmaceutical sector have seen a substantial decline [28][29] - The report highlights that the medical insurance fund's income and expenditure growth rates are stabilizing, indicating a long-term trend towards cost control in medical insurance, which is essential for the sustainable development of the innovative drug industry [31][36]

Group 1: Economic Outlook - The U.S. economy is expected to maintain moderate growth in the coming year, supported by factors such as Federal Reserve interest rate cuts and AI investments [1] - The Hong Kong stock market is anticipated to shift from valuation-driven to profit growth-driven, with a projected earnings growth rate of 6% to 10% for the Hang Seng Index [1] Group 2: Market Dynamics - The valuation expansion in the Hong Kong market may weaken, but liquidity will remain supportive, leading to a new supply creating new demand [1] - The dual liquidity easing in both China and the U.S. is expected to increase foreign and southbound capital supply, translating into new demand for Hong Kong stocks [1] Group 3: Sector Analysis - The U.S. tech sector is expected to become more rational, with AI continuing to be a key driver, while the regulatory environment will favor mergers and acquisitions [2] - The domestic pharmaceutical and innovative drug sectors are likely to benefit from a resurgence in M&A activity from large multinational companies [2] - The automotive sector is projected to see flat or slightly declining sales, presenting opportunities to gradually accumulate stocks of companies with high earnings growth certainty [2] Group 4: Recommended Stocks - Top stock picks for the first quarter of next year include Alphabet (GOOGL.US), Meta (META.US), Netflix (NFLX.US), Tencent Holdings (00700), Alibaba (BABA.US), and others [3]

Core Viewpoint - The innovation drug sector in China is experiencing significant growth due to favorable policy developments, with the introduction of new drug listings in the national medical insurance catalog and commercial insurance, providing a stable policy outlook for innovative drug companies [1][2]. Group 1: Industry Trends - The China Hong Kong Stock Connect Innovation Drug Index increased by 0.30% as of December 11, 2025, with notable gains from companies such as Zhaoyan New Drug (+4.15%) and Rongchang Bio (+2.85%) [1]. - The national medical insurance catalog for 2025 successfully added 114 new drugs, including 50 innovative drugs, achieving a historical high success rate of 88% [1]. - The introduction of dual catalogs for medical insurance and commercial insurance is expected to directly benefit innovative drug companies, indicating a positive industry outlook [1]. Group 2: Market Opportunities - The top ten weighted stocks in the China Hong Kong Stock Connect Innovation Drug Index account for 72.68% of the index, highlighting the concentration of investment in leading innovative drug companies [2]. - The Harvest Innovation Drug ETF (520970) closely tracks the index, providing investors with access to leading companies involved in drug research, development, and production [2]. - Investors without stock accounts can leverage the Hong Kong Stock Connect Innovation Drug ETF linked fund (024700) to capitalize on the growth opportunities in the innovative drug sector [2].